Strota/ Newsroom/ 2026-07-13

MANKIND (Mankind Pharma Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-07-13 · 11 Jul 13:28 · MANKIND stock page →

Mankind Pharma Limited has informed the Exchange about Acquisition Historically, acquisition / m&a events have moved MANKIND-type stocks in the bullish direction 48.9% of the next sessions (n=141).

Mankind Pharma has informed the National Stock Exchange of an acquisition, according to an exchange filing dated 11 July. The filing, published at 13:28, carries a "bullish" classification under the event type "Acquisition / M&A," though the document does not disclose deal size, target, or strategic rationale.

Events like this have historically shown a 48.9% win rate across 141 comparable instances, with a net edge of 0.213%, according to Strota's base-rate data. This means slightly less than half of similar acquisition announcements in the past have been followed by positive price movement, and the average historical outcome has been marginally positive. These figures describe the historical pattern for this event type, not a forecast for Mankind Pharma specifically.

The stock closed at ₹2,525.1 on 10 July, down 0.36% from the previous session, with a 14-day RSI of 58.1 indicating neutral momentum. It trades 7.05% below its 52-week high of ₹2,716.5 and 32.22% above its 52-week low of ₹1,909.7. The company commands a market capitalisation of ₹1,04,286 crore, with a price-to-earnings ratio of 54.64 and return on equity of 12.5%. In the derivatives segment, open interest rose 5.09% alongside a 0.22% price decline, classified as "Short Buildup" — indicating fresh short positions being added.

The exchange filing confirms an acquisition has occurred; it does not establish valuation impact, funding method, or earnings accretion. The historical base rate offers context for how markets have processed similar announcements, not predictive guidance for this specific transaction.

The catalyst

Mankind Pharma Limited has informed the Exchange about Acquisition (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

MANKIND right now

trading -0.36% on the day; F&O shows Short Buildup (OI 5.09% ); P/E 54.64; RSI 58.1. Full MANKIND analysis →

Sources

Mankind Pharma Limited has informed the Exchange about Acquisition — NSE
Mankind Pharma Shares In Focus As InCred Initiates Coverage, Eyes 11% Upside — Check Target Price — NDTV Profit
Mankind Pharma Ltd. Actuals & Estimates (NSE:MANKIND) — TradingView
MANKIND Forecast — Price Target — Prediction for 2027 — TradingView
Piramal Pharma, Cohance Lifesciences, Sun Pharma, Cipla, Dr Reddy's, other pharma shares jump; what's driving the rally? — Business Today

Keep digging

MANKIND — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
Newsroom: the other stocks in play this session.

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.